arrow
E

Eleonora Nicolò

Department of Medicine
H指数:16
被引数:1,194

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multi-analyte liquid biopsy characterization of metastatic inflammatory breast cancer: comparison with non-inflammatory breast cancer

多指标液体活检对转移性炎性乳腺癌的表征:与非炎性乳腺癌的比较

2026-08-060
OA
Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025

2025年国际炎性乳腺癌研讨会的重要科学成果与展望

Cancer
IF5.1
2026-05-140
PRE
Corrigendum to “International expert consensus on the clinical integration of circulating tumor cells in solid tumors” [Eur. J. Cancer 231 (2025) 116050]

勘误:“International expert consensus on the clinical integration of circulating tumor cells in solid tumors” [Eur. J. Cancer 231 (2025) 116050]

2025-12-100
PRE
International expert consensus on the clinical integration of circulating tumor cells in solid tumors

实体瘤中循环肿瘤细胞临床整合的国际专家共识

2025-10-200
PRE
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis

HR+/HER2−转移性乳腺癌中细胞周期蛋白依赖性激酶4/6抑制剂暴露后的循环基因组景观:一项回顾性多机构联盟分析

2025-08-160
OAAI
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study

转移性三阴性炎性乳腺癌患者的免疫检查点抑制剂 (integrle): 一项国际队列研究

2024-12-010
PRE
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2024-11-011
PRE
Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors

揭示循环肿瘤细胞的影响: 实体瘤的二十年发现和临床进展

2024-11-010
PRE
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials

年龄对早期临床试验中研究的新型癌症药物安全性和有效性的影响

2024-08-012
PRE
Immune checkpoint inhibitors for triple-negative inflammatory breast cancer (INCORPORATE): an international multicenter retrospective analysis
2024-05-020
PRE
Differential genomic profiling of progesterone receptor (PR) negative, estrogen receptor (ER) positive HER2-negative metastatic breast cancer (MBC) through circulating tumor DNA
2024-05-020
PRE
Association of tumor-derived extracellular vesicles with circulating tumor DNA alterations in metastatic breast cancer patients: exploring differences in inflammatory breast cancer
2024-05-020
PRE
Germline BRCA1/2 mutations detected by circulating tumor DNA testing in breast cancer patients: A retrospective mutiinstitutional analysis
2024-03-220
PRE